Circle, one of the world’s largest issuers of USDC, a stablecoin pegged to the U.S. dollar, ended its first trading day as a public company at $83.23 per share, 168% above its IPO price of $31 set the previous day.The IPO pop demonstrates public market investors’ interest in cryptocurrencies and stablecoins in particular amid the Trump administration’s supportive stance on crypto assets. The significant surge in Circle’s first-day trading could prompt institutional investors to set higher IPO prices for up ...

Core Viewpoint - Helius Medical Technologies, Inc. has announced a public offering of 2,768,600 shares of Class A common stock and accompanying warrants, priced at $3.27 per share, aiming to raise approximately $9.1 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The public offering includes 2,768,600 shares of Class A common stock and warrants to purchase an equal number of shares at a combined price of $3.27 per share [1]. - Each warrant will expire in 2.5 years from issuance, is immediately exercisable at an initial price of $7.3575 per share, and can be exchanged for 2.0 common shares under a zero cash exercise option [2]. - The offering is expected to close on June 6, 2025, subject to customary closing conditions [3]. Group 2: Regulatory and Contact Information - A registration statement on Form S-1 was filed with the SEC and declared effective on June 4, 2025, with a final prospectus to be available on the SEC's website [4]. - Electronic copies of the prospectus can be obtained from Maxim Group LLC, the sole placement agent for the offering [4][7].

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] Offering Details - Trevi announced a public offering of 17,400,000 shares of common stock at a price of $5.75 per share, aiming for total proceeds of $100 million before deductions [1] - The offering includes a 30-day option for underwriters to purchase up to 2,610,000 additional shares at the public offering price [1] - The offering is expected to close on or about June 5, 2025, subject to customary closing conditions [1] Underwriters - Morgan Stanley, Leerink Partners, Stifel, and Cantor are acting as joint book-running managers for the offering [2] Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3]

Group 1 - Orange County Bancorp, Inc. announced a public offering of 1,720,430 shares of common stock at a price of $23.25 per share, with an additional option for underwriters to purchase up to 258,064 shares [1][2] - The total gross proceeds from the offering are expected to be approximately $40.0 million, potentially increasing to $46.0 million if the underwriters fully exercise their option [2] - The net proceeds will be used for general corporate purposes, including investments in the Bank, enhancing regulatory capital and liquidity, and potential strategic acquisitions, although there are no current plans for specific acquisitions [2] Group 2 - The offering is expected to close on June 5, 2025, subject to customary closing conditions [2] - Piper Sandler & Co. and Stephens Inc. are acting as joint book-running managers for the offering [3] - Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company, which has approximately $2.6 billion in total assets, and Hudson Valley Investment Advisors, Inc. [6]

Core Viewpoint - Immunic, Inc. has successfully closed an underwritten public offering, raising approximately $65 million, with potential additional proceeds of up to $130 million from the exercise of warrants [1][3]. Group 1: Offering Details - The offering included pre-funded warrants, Series A warrants, and Series B warrants, with the Pre-Funded Warrants being immediately exercisable [1][2]. - Series A Warrants can be exercised until December 31, 2025, while Series B Warrants can be exercised starting October 1, 2025, until June 3, 2030 [2]. - The Series A and B Warrants will expire proportionally if the corresponding Pre-Funded Warrants are exercised before September 30, 2025 [2]. Group 2: Financial Aspects - The initial proceeds from the offering were approximately $65 million, before deducting underwriting discounts and commissions [3]. - The company may receive up to an aggregate of $130 million in additional proceeds if the Series A and Series B Warrants are fully exercised for cash [3]. Group 3: Use of Proceeds - The net proceeds from the offering will be used to fund clinical trials, operations, and other general corporate purposes [5]. Group 4: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [6]. - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [6]. - Other programs include IMU-856, targeting gastrointestinal diseases, and IMU-381, which is in preclinical testing [6].

Core Viewpoint - Orange County Bancorp, Inc. has launched an underwritten public offering of its common stock to support general corporate purposes, including investments in the Bank, regulatory capital, liquidity, and potential strategic acquisitions [1][2]. Group 1: Offering Details - The Company expects to grant underwriters a 30-day option to purchase additional shares of its common stock [1]. - The net proceeds from the offering will be used for general corporate purposes, which may include investments in the Bank, augmenting regulatory capital and liquidity, and potential strategic acquisitions [2]. Group 2: Regulatory Filings - The Company has filed a shelf registration statement and a preliminary prospectus supplement with the SEC for the offering [3]. - Investors are encouraged to read the preliminary prospectus supplement and accompanying prospectus for complete information about the Company and the offering [3]. Group 3: Company Background - Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company and Hudson Valley Investment Advisors, Inc., with total assets of approximately $2.6 billion [5]. - Orange Bank & Trust Company has a history of over 125 years, focusing on community and business clientele [5].

Hong Kong Exchanges (0388.HK) More listings and new product launches to drive further upside; Buy 30 May 2025 | 4:36PM HKT 0388.HK 12m Price Target: HK$455.00 Price: HK$400.40 Upside: 13.6% Although HKEX's share price has rallied ~35% ytd, on teens percent EPS upgrades and valuation expansion, it remains undervalued, in our view, relative to relatively strong recent market activity levels. Further, the listing pipeline has been building up with decent execution over the last few months. However, despite the ...

Company Overview - Siddhi Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aimed at effecting mergers, share exchanges, asset acquisitions, share purchases, recapitalizations, reorganizations, or similar business combinations with one or more businesses [5] IPO and Trading Information - Starting June 4, 2025, holders of units from the initial public offering can separately trade the Company's ordinary shares and rights [1] - The ordinary shares and rights will trade on The Nasdaq Global Market under the symbols "SDHI" and "SDHIR," respectively, while units that are not separated will continue to trade under the symbol "SDHIU" [2] - No fractional rights will be issued upon separation, only whole rights will be traded [2] Regulatory Information - The offering of the units was conducted via a prospectus, with copies available from Santander US Capital Markets LLC [3] - A registration statement on Form S-1 relating to these securities was filed with the SEC and declared effective on March 31, 2025 [3]

ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]